

## Declaration of Interest and Declaration of Confidentiality of ISoP Advisory Board members

This form consists of two parts, your personal details with biography, and the Public Declaration of Interests. It applies to the Executive Committee (EC) and Advisory Board members of the International Society of Pharmacovigilance.

Both parts of the form should be fully completed, signed, dated and return electronically to [administration@isoponline.org](mailto:administration@isoponline.org) with a short biography.

The Declaration of Interest and the biography will be published on isoponline.

### 1 Personal Details (please enclose your biography)

<b>First Name</b>	Manal
<b>Surname</b>	Younus
<b>Organisation</b>	Ministry of Health
<b>Country</b>	Iraq

\* I enclose my biography

I, Manal M.Younus, do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

### 2 Public Declaration of Interests

If you have interests to declare, please do so under the relevant questions. If you have no interests to declare, please indicate that the appropriate field is non-applicable. Please specify the interests that you currently have or have had in the past 5 years.

<b>Title/Function</b>	<b>Period of activity (within past 5 years)</b>	<b>Company* or organisation**</b>	<b>Description of the activity</b>
<b>1. Employment with a pharmaceutical company or an organisation</b>			
Head of Iraqi Pharmacovigilance Centre/ MOH	2016 till date	MOH	Manage all activities related to pharmacovigilance in both public and private sectors.
<b>2. Consultancy, advice or services with a pharmaceutical company or an organisation (including training)</b>			
Speaker in a	9 Nov.2019	Novo nordisk	presentation on

conference			understanding biosimilars
Advisory board	19 April 2019	Pfizer	Participation in one day activity covering the current concept of biosimilar and incomparable products
Symposium	14 Sept. 2018	Novartis	Presenting the role of pharmacovigilance in safety updates
Speaker in a conference	8 Dec. 2017	Novartis	Presenting the importance of integration of all regulatory activities.
<b>3. Strategic advisory role, member of professional societies, affiliation or equivalent structure</b>			
Elected board member (NGO)	May 2011- June 2016	Syndicate of Iraqi pharmacists	Regulate the profession at the private sector level
Member	2012 till date	FIP	SIG member in Personalised and Precision Medicine. SIG member in Regulatory Science and Quality.
<b>4. Grant / research funding including sponsorships, fellowships, non-monetary support</b>			
NA			
<b>5. Financial interests, direct shares of a pharmaceutical company, compensation, fees, honoraria (excluded investment trust without direct influence on shares)</b>			
NA			
<b>6. Patents</b>			
NA			
<b>7. Investigator (in a pharmaceutical industry instigated/sponsored clinical trial)</b>			
NA			
<b>8. Family member interest</b>			
NA			
<b>9. Any other interests or facts</b>			
NA			

*\* Pharmaceutical company (includes supply or service companies which contribute to the research, development production and maintenance of a medicinal product)*

*\*\* An organisation includes governmental, international or non-profit organisations (outside ISoP)*

Should there be any change to the information provided above due to the fact that I acquire additional interests, I shall promptly notify ISoP and complete a new Declaration of Interests detailing the changes.

I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the ISoP website.

Signature: Manal Mohammed Younus

Date: 27 Nov. 2019